论文部分内容阅读
今年,瑞典皇家科学院将2012年度诺贝尔化学奖授予了两名美国科学家,罗伯特·莱夫科维茨(Robert J.Lefkowitz,Robert在美国的小名为Bob)和他的学生布莱恩.科比尔卡(Brian K.Kobilka),以表彰他们在G蛋白偶联受体(GPCR)领域做出的奠基性贡献。Lefkowitz可以说是GPCR领域的奠基人之一。GPCR在基础科学和应用科学研究中都比较重要,特别是药物发现方面,40%的临床处方药均靶向这些蛋白。Lefkowitz关于GPCR的研究一直引领着药物学和药理学的发展脚步。Lefkowtitz不仅是
This year, the Royal Swedish Academy of Sciences awarded the 2012 Nobel Prize in Chemistry to two American scientists, Robert J. Lefkowitz (Robert’s nickname Bob in the United States) and his student Bryant Corbi Card (Brian K.Kobilka), in recognition of their G protein-coupled receptors (GPCR) made a groundbreaking contribution to the field. Lefkowitz can be said to be one of the founders of GPCR. GPCRs are important in both basic and applied scientific research, especially in drug discovery, where 40% of clinical prescription drugs target these proteins. Lefkowitz’s research on GPCRs has led the way in pharmacology and pharmacology. Lefkowtitz is not only